HK1146469A1 - Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation - Google Patents

Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation

Info

Publication number
HK1146469A1
HK1146469A1 HK11100630.3A HK11100630A HK1146469A1 HK 1146469 A1 HK1146469 A1 HK 1146469A1 HK 11100630 A HK11100630 A HK 11100630A HK 1146469 A1 HK1146469 A1 HK 1146469A1
Authority
HK
Hong Kong
Prior art keywords
agent
liposome preparation
tumor
oxaliplatin
enhancing
Prior art date
Application number
HK11100630.3A
Other languages
English (en)
Chinese (zh)
Inventor
龍弘 石田
弘志 際田
Original Assignee
國立大學法人德島大學
大鵬藥品工業株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人德島大學, 大鵬藥品工業株式會社 filed Critical 國立大學法人德島大學
Publication of HK1146469A1 publication Critical patent/HK1146469A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK11100630.3A 2008-01-30 2011-01-21 Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation HK1146469A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008019141 2008-01-30
JP2008306072 2008-12-01
PCT/JP2009/051499 WO2009096487A1 (ja) 2008-01-30 2009-01-29 オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤

Publications (1)

Publication Number Publication Date
HK1146469A1 true HK1146469A1 (en) 2011-06-10

Family

ID=40912832

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100630.3A HK1146469A1 (en) 2008-01-30 2011-01-21 Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation

Country Status (13)

Country Link
US (1) US8940327B2 (ja)
EP (1) EP2246056B1 (ja)
JP (1) JP5419716B2 (ja)
KR (1) KR101309440B1 (ja)
CN (2) CN103271922A (ja)
AU (1) AU2009209938B2 (ja)
CA (1) CA2713673C (ja)
ES (1) ES2500590T3 (ja)
HK (1) HK1146469A1 (ja)
RU (1) RU2492863C2 (ja)
SG (1) SG187515A1 (ja)
TW (1) TWI468188B (ja)
WO (1) WO2009096487A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
WO2010123078A1 (ja) * 2009-04-22 2010-10-28 大鵬薬品工業株式会社 腎細胞癌に対する化学療法の治療効果予測方法
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
ES2671926T3 (es) * 2011-05-25 2018-06-11 Taiho Pharmaceutical Co., Ltd. Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2883542B1 (en) * 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
CN105451720A (zh) * 2013-03-13 2016-03-30 马林克罗特有限公司 用于癌症疗法的脂质体奥沙利铂组合物
CN103211820B (zh) * 2013-04-25 2014-07-23 山东新时代药业有限公司 一种替吉奥胶囊的制备方法
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
WO2015031536A1 (en) 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
RU2706356C1 (ru) * 2018-12-27 2019-11-18 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ лечения онкологических заболеваний с помощью инъекций лекарственного препарата

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4910510B1 (ja) 1968-01-26 1974-03-11
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
CA1270198C (en) 1984-08-08 1990-06-12 Marcel B Bally ENCAPSULATION OF ANTINEOPLASTIC AGENTS IN LIPOSONES
DK0500953T3 (da) 1990-09-07 1997-01-06 Taiho Pharmaceutical Co Ltd Potentiator af antineoplastisk virkning og antineoplastisk middel
AU654555B2 (en) * 1991-05-27 1994-11-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
KR970701551A (ko) 1994-03-11 1997-04-12 고야 마사시 리포좀 제제(liposome preparation)
ES2206478T3 (es) * 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
JPH08169825A (ja) 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
ATE381932T1 (de) 1996-06-18 2008-01-15 Kyowa Hakko Kogyo Kk Liposomale zubereitungen von indolocarbazol- derivaten
DK0929293T3 (da) * 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
JP4468617B2 (ja) 2001-12-04 2010-05-26 デビオファーム エス．アー． 抗癌剤の併用投与方法及び併用可能な抗癌剤
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
DK1757283T3 (da) * 2004-06-09 2012-11-12 Taiho Pharmaceutical Co Ltd Antitumorvirkningsforstærker, antitumor middel og fremgangsmåde til cancerterrapi
KR100844477B1 (ko) * 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20060239925A1 (en) 2005-04-21 2006-10-26 Konica Minolta Medical & Graphic, Inc. Method of manufacturing pharmaceutical preparation containing liposomes
US20090074848A1 (en) * 2005-09-19 2009-03-19 Sharon Johnstone Combination formulations of cytidine analogs and platinum agents
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene

Also Published As

Publication number Publication date
US20100330166A1 (en) 2010-12-30
ES2500590T3 (es) 2014-09-30
AU2009209938A1 (en) 2009-08-06
RU2010136273A (ru) 2012-03-10
CN103271922A (zh) 2013-09-04
US8940327B2 (en) 2015-01-27
EP2246056A4 (en) 2011-01-12
TWI468188B (zh) 2015-01-11
KR101309440B1 (ko) 2013-09-23
JP5419716B2 (ja) 2014-02-19
CN101925356A (zh) 2010-12-22
TW200936182A (en) 2009-09-01
CA2713673C (en) 2014-01-14
CN101925356B (zh) 2014-06-11
WO2009096487A1 (ja) 2009-08-06
JPWO2009096487A1 (ja) 2011-05-26
KR20100126701A (ko) 2010-12-02
EP2246056A1 (en) 2010-11-03
EP2246056B1 (en) 2014-08-27
AU2009209938B2 (en) 2013-05-30
CA2713673A1 (en) 2009-08-06
RU2492863C2 (ru) 2013-09-20
SG187515A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
HK1146469A1 (en) Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
EP2124550A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE
HK1151791A1 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
HK1145965A1 (en) Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle
EP2269653A4 (en) COMPOSITION FOR THE STABILIZATION OF BLOCKER AND THE COMPOSITION COMPRISING TRANSDERMAL ABSORBABLE PREPARATION
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
EP2213679A4 (en) WATER SOLUBLE TRITERPENEPHENOL COMPOUNDS HAVING ANTI-TUMOR ACTIVITY AND PREPARATION THEREOF
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof
HK1147652A1 (en) Flavor improving agent
EP2345660A4 (en) ANTI-XDR-TB-MEDIUM, ANTI-MDR-TB-MEDIUM AND COMBINED ANTIBODY CLOUD
GB0718346D0 (en) Tooth-bleaching preparations
EP2192122A4 (en) Dithiolopyrrolone compounds and their preparation and use
EP2105140A4 (en) CANCER AGENT
KR100991431B9 (ko) 끈없는 비접착식 브라
GB0703452D0 (en) The edible,menthol toothpick
PL381690A1 (pl) Preparat biobójczy
IL212198A0 (en) Liposomal systems comprising sphingomyelin
AU320943S (en) Dress
GB0706854D0 (en) Skin lightening formulation
IL208987A0 (en) Cisatracurium derivatives, preparation and uses thereof
AU326204S (en) Dress
AU323844S (en) Dress
AU322741S (en) Dress
AU322866S (en) Dress
AU322867S (en) Dress

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230131